Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
N-benzylpyroglutamyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists.
Chen L, Tilley JW, Guthrie RW, Mennona F, Huang TN, Kaplan G, Trilles R, Miklowski D, Huby N, Schwinge V, Wolitzky B, Rowan K. Chen L, et al. Among authors: huby n. Bioorg Med Chem Lett. 2000 Apr 17;10(8):729-33. doi: 10.1016/s0960-894x(00)00089-5. Bioorg Med Chem Lett. 2000. PMID: 10782674
N-Cycloalkanoyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists.
Sidduri A, Tilley JW, Hull K, Lou JP, Kaplan G, Sheffron A, Chen L, Campbell R, Guthrie R, Huang TN, Huby N, Rowan K, Schwinge V, Renzetti LM. Sidduri A, et al. Among authors: huby n. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2475-8. doi: 10.1016/s0960-894x(02)00386-4. Bioorg Med Chem Lett. 2002. PMID: 12161161
Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures.
Bolin DR, Swain AL, Sarabu R, Berthel SJ, Gillespie P, Huby NJ, Makofske R, Orzechowski L, Perrotta A, Toth K, Cooper JP, Jiang N, Falcioni F, Campbell R, Cox D, Gaizband D, Belunis CJ, Vidovic D, Ito K, Crowther R, Kammlott U, Zhang X, Palermo R, Weber D, Guenot J, Nagy Z, Olson GL. Bolin DR, et al. Among authors: huby nj. J Med Chem. 2000 Jun 1;43(11):2135-48. doi: 10.1021/jm000034h. J Med Chem. 2000. PMID: 10841792
Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models.
Daouti S, Higgins B, Kolinsky K, Packman K, Wang H, Rizzo C, Moliterni J, Huby N, Fotouhi N, Liu M, Goelzer P, Sandhu HK, Li JK, Railkar A, Heimbrook D, Niu H. Daouti S, et al. Among authors: huby n. Mol Cancer Ther. 2010 Jan;9(1):134-44. doi: 10.1158/1535-7163.MCT-09-0601. Epub 2010 Jan 6. Mol Cancer Ther. 2010. PMID: 20053779
13 results